Documenting the histologic response of metastatic melanoma to combination therapy with BRAF and MEK inhibitors

Melanoma Res. 2022 Apr 1;32(2):127-129. doi: 10.1097/CMR.0000000000000784.

Authors

Karolina Mieczkowska¹, Jack Jacob¹, Luca Paoluzzi², Katia T Papalezova³, Beth N McLellan¹, Bijal Amin¹

Affiliations

¹ Department of Medicine, Division of Dermatology.
² Department of Medicine, Division of Oncology.
³ Department of Surgery, Division of Dermatology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.

PMID: 35254335
DOI: 10.1097/CMR.0000000000000784

No abstract available

Publication types

Letter

MeSH terms

Humans
Melanoma* / drug therapy
Melanoma* / pathology
Mitogen-Activated Protein Kinase Kinases
Neoplasms, Second Primary*
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use
Proto-Oncogene Proteins B-raf
Skin Neoplasms* / drug therapy

Substances

Protein Kinase Inhibitors
BRAF protein, human
Proto-Oncogene Proteins B-raf
Mitogen-Activated Protein Kinase Kinases